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Summary Recent work suggests that between 50 and 75% of small-cell lung cancer (SCLC) tumours have
specific high-affinity binding sites for somatostatin. This study evaluated the potential role of the radiolabelled
somatostatin analogue, ["l'In]pentetreotide, in the detection and staging of SCLC in patients prior to and after
chemotherapy using scintigraphic imaging techniques. Thirteen patients were studied prior to chemotherapy.
Following standard staging six patients had limited stage disease and seven extensive disease.
[I"'In]pentetreotide imaging led to the detection of all primary sites of disease, including a primary site of
disease not detectable with chest radiograph or computerised tomography (CT) of the thorax. Five of ten
metastatic sites detected by standard staging were also imaged. Furthermore, a cerebellar metastasis was
detected in a patient thought to have disease confined to the right hemithorax. This was subsequently
confirmed with a CT brain scan. Following chemotherapy ["'In]pentetreotide imaging detected residual
intrathoracic disease in two of three patients with complete remissions by standard staging and in two patients
who had had a partial response to chemotherapy. These results suggest that ["'In]pentetreotide imaging may
have a role to play in the clinical evaluation of patients with SCLC. Specifically, this technique may be of
particular value in detecting residual intrathoracic disease in patients thought to be in complete remission by
conventional staging methods.
Somatostatin is a tetradecapeptide that has a wide range of
biological activities functioning as a hormone release-
inhibitory factor, neurotransmitter, immunomodulator and
endogenous inhibitor of cell growth (Mescardo & Sherline,
1982; Reichlin, 1983a,b; Vehmeyer et al., 1986; Malec et al.,
1989). Somatostatin acts by binding to specific receptors
expressed by target tissues. Tumours with neuroendocrine
features may express specific high-affinity binding sites for
somatostatin (Reubi et al., 1990a).
Experimental studies have clearly demonstrated that the
majority of small-cell lung cancer (SCLC) tumours are
neuroendocrine. SCLC is characterised by the expression of
both pan-neuroendocrine markers and specific hormones and
their receptors, including bombesin/gastrin-releasing peptide
(GRP) and insulin-like growth factor 1 (IGF-1) (Cuttitta et
al., 1985; Moody et al., 1985; Macaulay et al., 1990;
Macaulay & Carney, 1991; Sheppard, 1991). Recent work
has demonstrated that SCLC tumours may synthesise
somatostatin and that between 50 and 75% have high-affinity
somatostatin binding sites (Bepler et al., 1988; Taylor et al.,
1988a; Bogden et al., 1990; Reubi et al., 1990b; Sagman et
al., 1990; Macaulay et al., 1991).
The radiolabelled somatostatin analogue ['231-tyr']octreo-
tide has been successfully used in scintigraphic imaging to
detect neuroendocrine tumours, including gastrointestinal
and pancreatic APUDomas and paragangliomas (Krenning
et al., 1989; Lamberts et al., 1990a,b; Kwekkeboom et al.,
1991). However, it is an expensive preparation with very high
hepatobiliary accumulation and a short effective half-life.
Furthermore, difficulties in labelling tyr'-octreotide with 1231
mean that such scans can only be performed in specialist
centres. The newly developed preparation ["'In]pentetreotide,
["'In]diethylenetriaminopentaacetic acid-linked SMS 201 995
(octreotide), may be prepared in any nuclear medicine de-
partment, is less expensive, is excreted predominantly by the
kidney and has a long effective half-life (Krenning et al.,
1992a). Encouraging results have already been obtained with
this analogue in imaging neuroendocrine tumours and lym-
phomas (Krenning et al., 1992a,b, 1993; Van Hagen et al.,
1993).
The purpose of this study was to evaluate, through scinti-
graphic imaging, the efficacy of ["'lnjpentetreotide in the
detection and staging of SCLC prior to chemotherapy and in
the assessment of tumour response to treatment.
Patients and methods
The study was approved by the ethics committees of the
hospitals involved. Patients were only included after giving
their informed written consent. Thirteen patients with histo-
logically proven SCLC were evaluated prior to chemo-
therapy, including three women and ten men (age range
29-68 years).
Each patient was assessed with a physical examination, full
blood count, renal, liver and bone biochemistry, a chest
radiograph and computerised tomographic (CT) imaging of
the thorax and upper abdomen with (nine patients) or with-
out abdominal ultrasonography. Radioisotope bone scan
imaging was performed in all but one patient. Nine patients
also had bone marrow aspirates and bone biopsies, including
the patient who did not have a bone scan. If indicated
clinically, further relevant investigations were performed.
Following evaluation the patient was defined as having either
limited or extensive disease. Limited disease was defined as
disease confined to a radiation port, i.e. to a hemithorax
including the ipsilateral and contralateral hilar, the medias-
tinal and the ipsilateral supraclavicular lymph nodes.
Evidence of spread of the tumour beyond this point was
defined as extensive disease (Minna et al., 1989).
Following chemotherapy four patients were re-evaluated.
A further patient with extensive disease, imaged with
["'In]pentetreotide after his first course ofchemotherapy, was
also assessed following completion of treatment.
The ["'In]pentetreotide, supplied by Mallinckrodt Medical
(The Netherlands), was administered as an intravenous bolus
injection. Prior to injection the pentetreotide was labelled
with indium-111 as previously described (Krenning et al.,
1992a) in the nuclear medicine department as a single-step
procedure and percentage binding calculated. Percentage bind-
ing was >97% in all cases. Total radioactivity administered
to the patients varied from 74 to 125 MBq.
Scintigraphic images were obtained 4 and 24 h post
administration using gamma-cameras with medium-energy
parallel-hole collimators. Two energy peaks were used, 171
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and 245 keV, each with a 20% window. Images of the thorax
and abdomen were obtained at 4 h. Images of the head and
neck, thorax, abdomen and pelvis were obtained at 24 h.
The planar images were followed by single-photon emis-
sion computed tomographic (SPECT) acquisitions of the
thorax and liver in a number of cases using an IGE 400 ACT
gamma-camera employing an elliptical 360° orbit with 64
projections at 20 s per projection.
Results
Pretreatment assessment
Following standard staging six patients were found to have
limited disease, while seven had extensive disease. Of those
patients with extensive disease, four had liver metastases,
four bony involvement, one a single large brain metastasis
and one an adrenal metastasis.
Scintigraphic imaging with ["'In]pentetreotide led to the
detection of all primary sites of disease. This included a
patient in whom the primary tumour, detected at broncho-
scopy, could not be visualised by other radiological tech-
niques (Figure 1).
In those patients with known extensive disease, patchy
uptake within the liver, consistent with metastases, was noted
in three of four patients and skeletal disease was detected in
two of the four patients. The brain and adrenal metastases
were not detected. In one patient a previously undetected
brain metastasis was found which had not been suspected
following routine staging (Figure 2). This was later confirmed
with a CT brain scan. As a result the patient was restaged as
having extensive disease.
Scintigraphic imaging with ["'In]pentetreotide resulted in 9
of 13 patients being correctly staged (sensitivity 69%), detec-
tion of five of ten known metastatic and one previously
unknown site (overall sensitivity 56%), down-staging of
disease in four of seven patients with extensive disease and
upstaging of disease in one patient with limited disease
(Tables I and II). Therefore, of the eight patients found to
have metastases at the completion of all investigations,
["'In]pentetreotide detected secondaries in four, or 50%.
Post-chemotherapy assessment
Four patients, two with limited disease and two with exten-
sive disease, were re-evaluated with [1'1In]pentetreotide fol-
lowing chemotherapy. Another patient with extensive disease
imaged with ["llIn]pentetreotide after completion of his first
cycle of chemotherapy was also assessed after completion of
treatment.
Case I A 43-year-old man with limited disease was treated
with six cycles of carboplatin and etoposide combination
chemotherapy. Following treatment he was assessed with a
full blood count (FBC), renal, liver and bone biochemistry,
bronchoscopy, chest radiography (CT) of the thorax and
upper abdomen and isotope bone scan imaging. No residual
disease was detected. ["l'In]pentetreotide scintigraphy
revealed an area of pathological uptake in the region of the
original disease (Figure 3). Subsequent magnetic resonance
imaging confirmed the finding. As no histological proof of
residual disease had been obtained it was decided to observe
the patient only. The patient subsequently had a full clinical
relapse of his disease at the primary site and developed
intracerebral metastases, which were treated with palliative
radiotherapy. He died 15 months after his initial diag-
nosis.
Case 2 A 34-year-old man with extensive disease was
treated with six cycles of combination cisplatin and
etoposide. Following treatment he was assessed as in case 1
together with an ultrasound of the abdomen but without
bronchoscopy. CT of the thorax detected several nodules in
the region of the original intrathoracic primary. These were
Figure 1 Anterior image of the thorax 24 h post injection.
Pathological uptake of the radiolabel is seen in the region of the
left hilum (P) in keeping with the site of the small-cell lung
tumour found at bronchoscopy. This tumour was not detectable
using standard radiological methods. Non-specific uptake is seen
in the thyroid (T), liver (L) and spleen (S).
Figure 2 A left lateral view of the skull 24 h post injection.
Pathological uptake of the radiolabel is noted in the region of the
cerebellum (C) consistent with a metastasis. The apex of the
primary intrathoracic tumour (P) is also seen. Non-specific
uptake is noted in the thyroid gland (T).
also detected with ["'In]pentetreotide imaging. The patient
was commenced on maintenance oral etoposide and is cur-
rently being observed as an out-patient.
Case 3 A 53-year-old man with limited disease was restaged
following treatment with five cycles of doxorubicin, cyc-
lophosphamide and etoposide as in case 1. No residual
disease was detected. ['llIn]pentetreotide imaging failed to
detect any residual disease. This man had previously had a
primary squamous cell tumour at the same site treated with
radiotherapy in 1982. As a result he underwent a
pneumonectomy following chemotherapy. Histological
evaluation of the resected lung and associated lymph nodes
failed to reveal any evidence of residual disease. He is being
followed up as an out-patient at present and remains
clinically disease free 20 months after commencing treat-
ment.
Case 4 A 61-year-old man with extensive disease had a
partial remission following chemotherapy with three cycles of
doxorubicin, cyclophosphamide and etoposide and three
cycles of carboplatin and etoposide. Evidence of residual764 K.J. O'BYRNE et al.
disease was detected on bronchoscopy, chest radiography and
liver biochemistry. [1l'In]pentetreotide imaging revealed
evidence of intrathoracic disease but did not detect evidence
of liver metastases. He received no further treatment and
died 13 months after diagnosis.
Case S A 46-year-old man with extensive disease on evalua-
tion prior to chemotherapy was re-evaluated with FBC,
renal, liver and bone biochemistry, chest radiography and CT
of the thorax and upper abdomen following treatment with
Table I Sites detected with scintigraphic imaging of SCLC patients
(n = 13) before chemotherapy compared with standard staging
methods
No. of sites detected
Standard ["'In]Pentreotide
Site of disease staging imaging
Thorax 13 13
Liver 4 3
Bone 4 2
Adrenal 1 0
Brain I 1*
All primary tumours, 5/10 metastatic sites of disease and one new
metastasis (1*) were detected with [l'In]pentetreotide.
Table II Comparison of SCLC stage (n = 13) following standard
evaluation with stage following ["'In]pentreotide scintigraphy
Standard ["'In]Pentreotide
Stage staging imaging
LD 6 9
ED 7 4*
LD, limited stage disease; ED, extensive stage disease.
4* = includes the patient in whom a previously unsuspected brain
metastasis was detected.
Table III Staging of SCLC tumours (n = 5) post chemotherapy
Standard ["'IniPentreotide
Response staging imaging
CR 3 1
PR 2 4
CR, complete response; PR, partial response.
six cycles of carboplatin and etoposide. No residual disease
was detected. [1l'In]pentetreotide imaging revealed evidence
of disease at the site of the original primary. He has received
no further treatment and is currently being observed as an
out-patient.
Therefore ["'In]pentetreotide imaging detected evidence of
residual disease in two patients, one with limited disease and
one with extensive disease prior to treatment, in whom con-
ventional methods suggested a complete remission (Table
III). While non-specific, physiological accumulation of the
radiolabel was noted in the spleen, kidneys and urinary tract,
liver and gastrointestinal tract, pituitary and thyroid gland,
no false-positive results were recorded (specificity 100%).
SPECT imaging improved the anatomical localisation of
disease in the thorax but contributed little to the overall
assessment.
Discussion
Small-cell lung cancer remains a disease with a poor prog-
nosis despite being sensitive to both chemotherapy and
radiotherapy. The median survival for patients with limited
disease is in the region of 16 months with 5 year survival
being achieved in 7-20% of patients. With extensive disease
the median survival is 9 months with few long-term sur-
vivors. Therefore staging has a significant impact on prog-
nosis and, in some cases, on the management of patients
(Minna et al., 1989; Hansen, 1992).
Recent experimental evidence suggests that neuroendocrine
tumours may express receptors or high-affinity binding sites
for somatostatin (Krenning et al., 1989, 1992a,b; Lamberts et
al., 1990a,b; Kwekkeboom et al., 1991; Reubi et al., 1990a).
In vitro evidence suggests that between 50 and 75% of SCLC
tumours have specific high-affinity binding sites for somatos-
tatin (Taylor et al., 1988a; Bogden et al., 1990; Reubi et al.,
1990b; Sagman et al., 1990; Macaulay et al., 1991). Further-
more, SCLC disease sites were located in five of eight
patients using [13I-tyr3]octreotide (Kwekkeboom et al., 1991),
while the primary sites of disease have been imaged in all
patients evaluated with ["llIn]pentetreotide to date (Krenning
et al., 1992b, 1993).
This study is the first to evaluate ["'In]pentetreotide scinti-
graphy as a staging modality prior to chemotherapy and in
the assessment of disease response after treatment. Our
results substantiate earlier findings. In all cases the primary
SCLC tumour was detected, including in one patient in whom
Figure 3 Anterior views of the thorax 24 h post injection of a patient with limited stage disease small-cell lung cancer before and
after completion of treatment. The pretreatment image on the left shows disease in the right perihilar region. The post-therapy
image is shown on the right. A small area of residual disease is noted in the same area. This could not be detected with standard
staging methods. Non-specific uptake is noted in the liver (L), spleen (S) and kidneys (K).["'In]PENTETREOTIDE SCLC IMAGING 765
primary site, detected at bronchoscopy, could not be
visualised with standard radiological techniques.
All sites of metastatic disease were visualised in 50% of the
patients with extensive disease at the completion of all inves-
tigations. This included one patient in whom a previously
unsuspected cerebellar metastasis was localised. This resulted
in restaging of his disease from limited disease to extensive
disease.
The detection of the intracranial metastasis raises the ques-
tion as to whether or not CT brain scanning should be
routine in the assessment of patients with presumed limited
SCLC prior to treatment. Several studies have demonstrated
that the detection rate of asymptomatic brain metastases is
low - in the region of 10% of all new cases of SCLC.
Furthermore, current evidence suggests that patients with
brain metastases as the only site of extensive disease have a
median survival not markedly different from that of patients
with limited disease, although long-term survival is rare
(Minna et al., 1989; Hardy et al., 1990). Therefore, at the
present time, routine CT brain scanning at presentation is
not recommended in patients without other clinical evidence
of intracranial disease.
Following staging all patients received etoposide-based
chemotherapy in combination with doxorubicin and cyclo-
phosphamide or cisplatin or carboplatin. The patient with
the cerebellar metastasis detected by ["'11n]pentetreotide
imaging received cranial irradiation as well as systemic car-
boplatin and etoposide chemotherapy.
["'In]pentetreotide imaging proved more effective than
conventional staging methods in detecting residual intra-
thoracic disease following completion of treatment, localising
sites of disease in two patients otherwise thought to be in
complete remission. Therefore, the technique appears to
allow a more accurate assessment of prognosis to be made in
an individual patient following completion of therapy and
may aid subsequent management decisions. Use of this imag-
ing modality may be of particular importance in the evalua-
tion of the response of SCLC tumours to novel forms of
treatment.
The reason for non-visualisation of the metastases in 50%
of cases is unclear. Non-specific uptake of the radiolabel seen
in the spleen, kidneys and urinary tract, liver and gastrointes-
tinal tract, pituitary and thyroid gland may obscure visualisa-
tion of metastases to these areas. However, the lack of
uptake of radiolabel by bone and brain deposits cannot be
explained in this way. This raises a number ofpossibilities. In
a proportion of cases the metastatic disease may represent a
dedifferentiated clone of the primary SCLC tumour not exp-
ressing somatostatin receptors. Local factors may also be
playing a role in individual patients either by down-
regulating somatostatin receptor expression or, if high local
levels of endogenous somatostatin are being produced, by
blocking the receptor site, thereby inhibiting visualisation of
the disease. Finally, in image-negative metastatic disease it is
possible that the SCLC cells themselves are not expressing
specific somatostatin binding sites. Rather it may be that the
primary tumour is being visualised because of uptake of the
radiolabel by the local inflammatory response, as activated
immune cells are known to express somatostatin receptors
(Nakamura et al., 1987; Sreedharan et al., 1989). If this were
the case then those patients in whom the metastases are seen
may represent the true proportion of patients with metastatic
SCLC tumours that express high-affinity binding sites for
somatostatin - 50% of patients with extensive disease
evaluated in this study. This would be in keeping with the
known in vitro data.
Novel approaches to therapy in SCLC are currently being
assessed and include inhibiting the action of autocrine
growth factors such as GRP with GRP antagonists and GRP
receptor antibodies (Cuttitta et al., 1987; Macaulay &
Carney, 1991; Carney, 1992). Somatostatin analogues are
currently being evaluated as possible therapeutic agents in
SCLC. In vitro studies have demonstrated that somatostatin
analogues may inhibit the clonal growth of SCLC cell lines.
Somatostatin analogues also inhibit vasoactive intestinal
polypeptide-induced cAMP accumulation in SCLC cells
(Taylor et al., 1988b, 1991). The growth of SCLC xenografts
has been inhibited in athymic nude mice (Taylor et al.,
1988b; Bogden et al., 1990; Macaulay et al., 1991). These
results suggest that SCLC somatostatin receptors are func-
tional and that the growth-inhibitory effect is direct through
inhibition of specific growth pathways within the tumour
cells. Somatostatin analogues may also have indirect growth-
inhibitory effects through the inhibition of growth factors
released from other tissues, such as IGF-1 and epidermal
growth factor (Ghirlanda et al., 1983; Macaulay et al., 1991;
Damstrup et al., 1992).
Imaging of SCLC tumours with ["'In]pentetreotide may
have a role to play in identifying those patients most likely to
respond to somatostatin analogue therapy. Of great
significance in this regard is the efficacy of this agent in
detecting residual SCLC disease, suggesting that treated
SCLC tumours continue to express somatostatin receptors.
This lays the groundwork for evaluation of somatostatin
analogues as therapeutic agents in the treatment of
chemotherapeutically debulked SCLC disease in the
future.
The possibility of using radiolabelled antibodies to treat a
wide range of tumours has yielded interesting data (Larson,
1987; Goldenberg, 1991). However, one of the principal pro-
blems encountered includes the generation of host antibody
response to the administered agent rendering the radiolabel
useless (Goldenberg, 1991). The possibility of employing a
radiolabelled chelated somatostatin analogue as a radiothera-
peutic agent in treating somatostatin receptor-positive SCLC
tumours is an exciting prospect for the future. As somato-
statin analogues are based on sequences of host circulating
hormone they rarely induce immunisation (Krenning et al.,
1993). The accumulation of["'In]pentetreotide in gastrointes-
tinal APUDomas is between 0.0123% and 0.2% of the
administered dose per gram of tumour tissue. The rapid
clearance of the radiolabel from the blood, the relatively low
accumulation in the liver (1.9% and 2.2% of the adminis-
tered dose at 4 and 24 h respectively) with resultant relatively
low excretion into the gastrointestinal tract, and, finally, the
predominant renal clearance are advantageous in this regard.
However, the amount of renal accumulation and the rela-
tively long renal effective half-life will limit the maximally
applicable radiation dose. Studies are required to investigate
how to lower the renal radioactivity (Krenning et al.,
1993).
In conclusion, (a) the imaging of all disease sites at a single
sitting in a significant proportion of patients with extensive
disease, thereby making further investigations unnecessary,
(b) the localisation of otherwise unexpected metastatic
deposits and (c) the detection of residual disease not found
by other means suggest that [1l'In]pentetreotide may be a
useful adjunct in the diagnostic evaluation of patients with
SCLC.
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